BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• Business

  Biomagnetics Diagnostics Corporation Retains Emerging Growth Research, LLP for Public and Investor Relations

  September 14, 2009

   · 

  1 min read
• Orbus Neich’s Genous(TM) Bio-engineered R stent(TM) is Feasible in Patients Requiring Undeferrable Non-Cardiac Surgery, International Journal of Cardiology Publication Reports

  September 14, 2009

   · 

  1 min read
• Genetown

  Charles River Laboratories (Massachusetts) to Present at September Conferences

  September 14, 2009

   · 

  1 min read
• Pharm Country

  Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV

  September 14, 2009

   · 

  1 min read
• Drug Development

  Detailed Data From Vical Incorporated’s TransVax(TM) CMV Vaccine Phase 2 Trial Presented in Late-Breaker Session at ICAAC

  September 14, 2009

   · 

  1 min read
• Biotech Bay

  In Vitro Study of Adamas Pharmaceuticals’ Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses

  September 14, 2009

   · 

  2 min read
• Business

  Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics’ Board of Directors as Chair

  September 14, 2009

   · 

  1 min read
• Biotech Bay

  Nile Therapeutics, Inc. Announces Poster Presentation at 2009 Heart Failure Society of America Annual Meeting

  September 14, 2009

   · 

  1 min read
• Drug Development

  Artielle ImmunoTherapeutics, Inc. Announces Positive Results of Phase 1 Multiple Sclerosis Trial Results Presented at 13th Congress of the European Federation of Neurological Societies in Florence, Italy

  September 14, 2009

   · 

  2 min read
• Drug Development

  Enobia Pharma Announces Positive Clinical Results With ENB-0040, a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia

  September 14, 2009

   · 

  1 min read